Chang M Li

US Patent:

20220380776, Dec 1, 2022

Filed:

Oct 22, 2020

Appl. No.:

17/771128

Inventors:

- Seattle WA, US
Roland B. Walter - Seattle WA, US
Andre Lieber - Seattle WA, US
Chang Li - Seattle WA, US

Assignee:

Fred Hutchinson Cancer Center - Seattle WA
University of Washington - Seattle WA

International Classification:

C12N 15/113
C12N 5/00
C12N 5/0789
C12N 9/22

Abstract:

Systems and methods to selectively protect therapeutic cells by reducing CD33 expression in the therapeutic cells using base editors and targeting non-therapeutic cells with an anti-CD33 therapy are described. The selective protection results in the enrichment of the therapeutic cells while simultaneously targeting any diseased, malignant and/or non-therapeutic CD33 expressing cells within a subject.

US Patent:

20220257796, Aug 18, 2022

Filed:

Jul 2, 2020

Appl. No.:

17/618774

Inventors:

- Seattle WA, US
Chang Li - Seattle WA, US
Hongjie Wang - Seattle WA, US

Assignee:

Fred Hutchinson Cancer Research Center - Seattle WA
University of Washington - Seattle WA

International Classification:

A61K 48/00
C12N 15/11
C12N 15/113
C12N 15/90
C12N 15/86
C12N 9/22

Abstract:

The present disclosure provides, among other things, helper-dependent adenoviral serotype 35 (Ad35) vectors. In various embodiments, helper-dependent Ad35 vectors can be used to deliver a therapeutic payload to a subject in need thereof. Exemplary payloads can encode replacement proteins, antibodies, CARs, TCRs, small RNAs, and genome editing systems. In certain embodiments, a helper-dependent Ad35 vector is engineered for integration of a payload into a host cell genome. The present disclosure further includes methods of gene therapy that include administration of a helper-dependent Ad35 vector to a subject in need thereof.